Literature DB >> 11082041

Ectodomain shedding, translocation and synthesis of SorLA are stimulated by its ligand head activator.

W Hampe1, I B Riedel, J Lintzel, C O Bader, I Franke, H C Schaller.   

Abstract

The single transmembrane receptor SorLA is the mammalian orthologue of the head activator-binding protein, HAB, from hydra. The human neuronal precursor cell line NT2 and the neuroendocrine cell line BON produce head activator (HA) and respond to HA by entry into mitosis and cell proliferation. They express SorLA, and bind HA with nanomolar affinity. HA coupled to Sepharose is able to precipitate SorLA specifically proving that SorLA binds HA. Using antisera directed against extra- and intracellular epitopes we find SorLA as membrane receptor and as soluble protein released from cells into the culture medium. Cell lines differ strongly in processing of SorLA, with NT2 cells expressing SorLA mainly as membrane receptor, whereas release predominates in BON cells. Soluble SorLA lacks the intracellular domain and is shed from the transmembrane protein by a metalloprotease. Release from cells and brain slices is stimulated by HA and by phorbol ester, and it is blocked by a metalloprotease inhibitor and by lowering the temperature to 20 degrees C. Blockade of SorLA shedding and treatment of cells with SorLA antisense oligonucleotides lead to a decrease in the rate of cell proliferation. From this we conclude that SorLA is necessary to mediate the mitogenic effect of endogenous HA. HA enhances the translocation of SorLA from internal membranes to the cell surface and its internalization. In addition, HA stimulates SorLA synthesis hinting at an autocatalytic feedback loop in which the ligand activates production, processing, and translocation of its receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082041     DOI: 10.1242/jcs.113.24.4475

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  22 in total

1.  Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing.

Authors:  Anja W Fjorback; Matthew Seaman; Camilla Gustafsen; Arnela Mehmedbasic; Suzanne Gokool; Chengbiao Wu; Daniel Militz; Vanessa Schmidt; Peder Madsen; Jens R Nyengaard; Thomas E Willnow; Erik Ilsø Christensen; William B Mobley; Anders Nykjær; Olav M Andersen
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

2.  Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members.

Authors:  Guido Hermey; Susanne S Sjøgaard; Claus Munck Petersen; Anders Nykjaer; Jørgen Gliemann
Journal:  Biochem J       Date:  2006-04-15       Impact factor: 3.857

Review 3.  [Regenerative medicine. New therapeutic methods in otorhinolaryngology and head and neck surgery].

Authors:  H Löwenheim
Journal:  HNO       Date:  2008-03       Impact factor: 1.284

Review 4.  Substrate specificity of gamma-secretase and other intramembrane proteases.

Authors:  A J Beel; C R Sanders
Journal:  Cell Mol Life Sci       Date:  2008-05       Impact factor: 9.261

5.  Neuronal LR11/sorLA expression is reduced in mild cognitive impairment.

Authors:  Kristen L Sager; Joanne Wuu; Susan E Leurgans; Howard D Rees; Marla Gearing; Elliott J Mufson; Allan I Levey; James J Lah
Journal:  Ann Neurol       Date:  2007-12       Impact factor: 10.422

6.  Nuclear signalling by tumour-associated antigen EpCAM.

Authors:  Dorothea Maetzel; Sabine Denzel; Brigitte Mack; Martin Canis; Philip Went; Michael Benk; Cuong Kieu; Peer Papior; Patrick A Baeuerle; Markus Munz; Olivier Gires
Journal:  Nat Cell Biol       Date:  2009-01-11       Impact factor: 28.824

7.  Soluble SORLA Enhances Neurite Outgrowth and Regeneration through Activation of the EGF Receptor/ERK Signaling Axis.

Authors:  Jessica Stupack; Xiao-Peng Xiong; Lu-Lin Jiang; Tongmei Zhang; Lisa Zhou; Alex Campos; Barbara Ranscht; William Mobley; Elena B Pasquale; Huaxi Xu; Timothy Y Huang
Journal:  J Neurosci       Date:  2020-06-29       Impact factor: 6.167

8.  SorLA complement-type repeat domains protect the amyloid precursor protein against processing.

Authors:  Arnela Mehmedbasic; Sofie K Christensen; Jonas Nilsson; Ulla Rüetschi; Camilla Gustafsen; Annemarie Svane Aavild Poulsen; Rikke W Rasmussen; Anja N Fjorback; Göran Larson; Olav M Andersen
Journal:  J Biol Chem       Date:  2014-12-18       Impact factor: 5.157

9.  An alternative transcript of the Alzheimer's disease risk gene SORL1 encodes a truncated receptor.

Authors:  Jenny Blechingberg; Annemarie Svane Aavild Poulsen; Mads Kjølby; Giulia Monti; Mariet Allen; Anne Kathrine Ivarsen; Sarah J Lincoln; Gangadaar Thotakura; Christian B Vægter; Nilüfer Ertekin-Taner; Anders Nykjær; Olav M Andersen
Journal:  Neurobiol Aging       Date:  2018-06-28       Impact factor: 4.673

10.  Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease.

Authors:  Sara E Dodson; Olav M Andersen; Vinit Karmali; Jason J Fritz; Dongmei Cheng; Junmin Peng; Allan I Levey; Thomas E Willnow; James J Lah
Journal:  J Neurosci       Date:  2008-11-26       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.